Mitchell Cairo
New York Medical College · New York Medical Center · Columbia University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mitchell Cairo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:42 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07575893 · CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin LymphomaNew York Medical College · not yet recruiting · Classical Hodgkin Lymphoma · principal investigator
- Ph3NCT07225972 · Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC AloneNew York Medical College · recruiting · CMV, AdV Infection, AdV Reactivation · principal investigator
- Ph2NCT05987124 · Defibrotide Dose-escalation for SOS Post-HSCTNew York Medical College · recruiting · Sinusoidal Obstruction Syndrome, Veno-occlusive Disease · principal investigator
- Ph2NCT05564598 · CMV CTLs in Neonates With CMV InfectionNew York Medical College · recruiting · Congenital Cytomegaloviral (CMV) Disease · principal investigator
- Ph2NCT05253495 · Chemoradiotherapy With Targeted Immunotherapy in Pediatric LymphomaNew York Medical College · recruiting · Non-hodgkin Lymphoma, Hodgkin Lymphoma · principal investigator
- Ph1NCT04972942 · Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & LymphomaNew York Medical College · recruiting · T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma · study chair
- Early Ph1NCT03719105 · Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaNew York Medical College · recruiting · NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma · study director
- Ph2NCT03266653 · EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV InfectionNew York Medical College · recruiting · Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder · principal investigator
- Ph2NCT03266627 · Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus InfectionNew York Medical College · recruiting · Adenovirus, Primary Immune Deficiency Disorder · principal investigator
- N/ANCT03205657 · Auto/Allo Tandem Transplant for Relapsed B-NHLNew York Medical College · completed · Non Hodgkin Lymphoma · principal investigator
- Ph2NCT02675959 · Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell DiseaseNew York Medical College · recruiting · Sickle Cell Disease · principal investigator
- Ph2NCT02393157 · Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLNew York Medical College · recruiting · Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma · study chair
- Ph1NCT02164097 · ODSH + ICE Chemotherapy in Pediatric Solid TumorsNew York Medical College · terminated · Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma · principal investigator
- Ph1/Ph2NCT02098512 · Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma PatientsNew York Medical College · unknown · Hodgkin Lymphoma · principal investigator
- Ph1NCT02057445 · 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated LymphomaNew York Medical College · completed · Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder · principal investigator
- Ph1NCT00684255 · Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)New York Medical College · terminated · Systemic Lupus Erythematosus, Systemic Sclerosis · principal investigator
- Ph2NCT00057811 · Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or LymphomaChildren's Oncology Group · completed · Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma · principal investigator
- Ph1NCT00036855 · Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaNational Cancer Institute (NCI) · terminated · AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Randomized Study of Maternal Donor Derived CMV Cytotoxic T-Lymphocytes (CTLs) and Valganciclovir vs Valganciclovir in Neonates With Moderate/Severe Maternal Acquired CMV InfectionR01FD007837 · FDA · NEW YORK MEDICAL COLLEGE · fiscal years 2023 to 2026 · $324,998 awarded in 2026Same name and institution; not confirmed by an ID
- Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK cell against Ewing sarcomaU54CA232561 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · fiscal years 2022 to 2023 · $253,700 awarded in 2023Same name and institution; not confirmed by an ID
- CMV, ADV and EBV Viral Cytotoxic T-Lymphocytes Generated by a Novel Cytokine Capture System in Children,Adolescents and Young Adults with Refractory Viral Infection and T-Cell ImmunodeficiencyR01FD006363 · FDA · NEW YORK MEDICAL COLLEGE · fiscal years 2019 to 2022 · $428,718 awarded in 2022Same name and institution; not confirmed by an ID
- Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin LymphomaR13CA275201 · NCI · NEW YORK MEDICAL COLLEGE · fiscal years 2022 · $4,475 awarded in 2022Same name and institution; not confirmed by an ID
- Phase 2 Defibrotide PPX in High Risk SCD Pts w/MAC&Haplo AlloSCT IND127812 9-3-15R01FD004090 · FDA · NEW YORK MEDICAL COLLEGE · fiscal years 2012 to 2020 · $499,999 awarded in 2020Same name and institution; not confirmed by an ID
- Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin LymphomaR13CA232383 · NCI · NEW YORK MEDICAL COLLEGE · fiscal years 2018 · $10,000 awarded in 2018Same name and institution; not confirmed by an ID
- 1st Annual Tandem ASPHO/PBMTC Educational Mtg: New Frontiers in Pediatric AlloSCTR13CA177155 · NCI · NEW YORK MEDICAL COLLEGE · fiscal years 2013 · $5,000 awarded in 2013Same name and institution; not confirmed by an ID
- Fourth International Symposium on Childhood, Adolescent and Young Adult Non-HodgkR13CA171748 · NCI · NEW YORK MEDICAL COLLEGE · fiscal years 2012 · $15,000 awarded in 2012Same name and institution; not confirmed by an ID
- First Int'l Symposium on Childhood and Adolescent NHLR13CA101951 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2003 · $25,000 awarded in 2003Same name and institution; not confirmed by an ID
- Nonablative AlloSCT in Refractory Autoimmune DiseaseR21AR049330 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2002 to 2003 · $81,750 awarded in 2003Same name and institution; not confirmed by an ID
- COLLECTION AND STORAGE CENTER FOR CLINICAL RESEARCHN01HB067140 · NHLBI · CHILDREN'S HOSPITAL OF ORANGE COUNTY · fiscal years 1996 to 1998 · $185,810 awarded in 1998Same name and institution; not confirmed by an ID
- TRANSPLANT CENTER FOR UMBILICAL CORD STEM CELLN01HB067136 · NHLBI · CHILDREN'S HOSPITAL OF ORANGE COUNTY · fiscal years 1996 to 1998 · $2,006 awarded in 1998Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Children's Oncology Group Chair's GrantU10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013Named on NCT00057811
- Children's Oncology Group Phase 1 / Pilot ConsortiumU01CA097452 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI SUSAN M. BLANEY · fiscal years 2002 to 2011Named on NCT00036855
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:42 UTC. The ranking covers the 200 most relevant of 90 PubMed records, and a shared surname and initials can bring in a namesake. All 90 on PubMed
- Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.N Engl J Med · 2001668 citationsRCR 15.1
- 507 citationsRCR 13.4
- Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.J Clin Oncol · 2010388 citationsRCR 9.7
- Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study.Lancet Respir Med · 2020343 citationsRCR 18.2
- 311 citationsRCR 7.9
- 307 citationsRCR 7.0
- 244 citationsRCR 5.4
- Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.J Clin Oncol · 2008153 citationsRCR 3.2
- A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.Biol Blood Marrow Transplant · 2006145 citationsRCR 3.5
- 139 citationsRCR 3.7